Abstract

Lassa fever is a tremendous fitness danger to West African human populations with lots of lots of annual cases. There are no authorized scientific countermeasures presently available. Compassionate use of the antiviral drug ribavirin or transfusion of convalescent serum has resulted in blended success relying on when administered or the donor source, respectively. We until now recognized quite a few recombinant human monoclonal antibodies focused on the glycoprotein of Lassa virus with sturdy neutralization profiles in vitro. Here, we show brilliant therapeutic efficacy the use of first-in-class human antibodies in a guinea pig mannequin of Lassa contamination thereby supplying a promising therapy alternative. Lassa virus (LASV) reasons extreme hemorrhagic fever with excessive mortality, but no vaccine presently exists. Antibodies focused on viral attachment proteins are integral for safety towards many viral infections.

Keywords: Clinical trial; Priority pathogens; Vaccine candidate; Vaccine development; Viral haemorrhagic fever